Costa
AC. The glutamatergic hypothesis for Down syndrome: the potential use of
N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration. CNS Neurol Disord Drug Targets. 2014 Feb;13(1):16–25.
[PubMed: 24152324]